Vanda Pharmaceuticals initiated with a Buy at Stifel. analyst Derek Archila initiated Vanda Pharmaceuticals with a Buy rating and $30 price target, citing the base business, Fanapt acceleration, and readouts from two meaningful clinical programs.
https://thefly.com/landingPageNews.php?id=2790379
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.